66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Oral

Research, Fundamental Science, Bleeding and Clotting, Lymphoid Leukemias, ALL, Translational Research, Hemophilia, Genetic Disorders, Diseases, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Emerging technologies, Biological Processes, Technology and Procedures, Miscellaneous Cellular Therapies, Gene editing

Ballroom 20AB (San Diego Convention Center)

Moderators:

Kazusa Ishii, MD, MPH, National Cancer Institute and David J. Young, MD, PhD, National Institute of Health

Disclosures:

No relevant conflicts of interest to declare.

For this session, we have selected six top scoring abstracts for oral presentation that develop novel engineered cell therapy approaches, or that investigate novel cell based delivery approaches.

9:30 AM

Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment

Nathan E Welty, MD, PhD¹, Patrick Mellors, MD¹, Olga Shestova, PhD¹^*, Darryl Sams²^*, Om Gandhi³^*, Joelle Kim⁴^*, Xinhe Shan, MD⁵ and Saar Gill, MD, PhD¹

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
³University of Pennsylvania, Philadelphia
⁴Baylor College of Medicine, Houston, TX
⁵Internal Medicine, Albert Einstein College of Medicine, New York City, NY

9:45 AM

iPSC-Derived CAR Neutrophils Possess Potent Activity Against Solid Tumors In Vivo

Aditi Majumder¹^*, MD Ehsanul Kabir²^*, Ho Sun Jung, Ph.D³^*, Yuju Jun⁴^*, Jue Zhang⁵^*, Anna Huttenlocher⁴^*, Christian Capitini⁶, James Thomson⁷^* and Igor Slukvin, MD^3,8,9

¹Wisconsin National Primate Research Center, Madison, WI
²Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI
³Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI
⁴University of Wisconsin Madison, Madison, WI
⁵Morgridge Instituet for Research, Madison, WI
⁶University of Wisconsin-Madison, Madison, WI
⁷Morgridge Institute for Research, Madison, WI
⁸Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI
⁹Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI

10:00 AM

Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity

Yuanyuan Tian, PhD¹^*, Bei Jia, MD, PhD²^*, Che Young Lee, BS¹^*, Qingrong Huang, PhD¹^*, Chenchen Zhao, MD²^*, Ciril Abraham, BS¹^*, Wenbin Mo, MMSc¹^*, Mimi Chen, PhD¹^*, Ying WANG¹^*, Hong Zheng, MD, PhD² and Yi Zhang, MD, PhD¹

¹Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
²Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA

10:15 AM

A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Anja F Hohmann¹^*, Timothy Mullen, PhD¹^*, Jasmine Edelstein, PhD¹^*, Swati Singh¹^*, Alexis Hubaud, PhD¹^*, Sarah Leach, PhD¹^*, Tracy Huang, PhD¹^*, Ella Liberzon, PhD¹^*, Wayne Bainter¹^*, Sean Keegan¹^*, Caroline Bullock¹^*, Shivani Bhawsar¹^*, Michael D Leiken¹^*, Katherine Molloy¹^*, Ryan Couto¹^*, Sakshisingh Thakur¹^*, Charuta Yadav¹^*, Troy Patterson¹^*, Amy Lundberg¹^*, Megan L Brophy, PhD¹^*, Toshiro K Ohsumi, PhD¹^*, Sol Shenker, PhD²^*, Monika Musial-Siwek, PhD¹^*, Adam S Lazorchak, PhD¹^*, Sean Arlauckas, PhD¹^*, Hanlan Liu, PhD¹^* and Richard A Morgan, PhD¹

¹Be Biopharma, Cambridge, MA
²Shenker Bioinformatics LLC, Belmont, MA

10:30 AM

Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies

Xiuiu Yang, MD^1,2^*, Shanwei Ye¹^*, Qian Xu, MD/PhD¹^*, Jue Wang³^*, Caroline Markmann, MD/PhD⁴^*, Lingfeng Zhang¹^*, Shujia Zhang¹^*, Xinyue Deng, MD/PhD⁵^*, Jiali Cheng, MD/PhD¹^*, Jia Wu¹^*, Vijay Bhoj, MD/PhD⁴^*, Zheng Zhang, MD/PhD⁶^* and Liang Huang, MD/PhD^1,2,7

¹Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China, Wuhan, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
³Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁴Department of Pathology & Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA, Philadelphia, PA
⁵Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China, Wuhan, China
⁶Department of Orthopedics, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, China
⁷Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China

10:45 AM

Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

Sophie Jamet¹^*, Huiyuan Zhang, PhD²^*, Sally Ditzler²^*, Kikki Tucker²^*, Peter Chong²^*, Clara Libbrecht, MD, PhD²^*, Ray Ruff²^*, Hailey Hentschel²^*, Bianka Haro²^*, Benjamin J Huang, MD³, James Olson, MD PhD²^*, Jason Price, PhD²^* and Mignon L. Loh, MD⁴

¹Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Insitute, Seattle, WA
²Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA
³Department of Pediatrics, University of California, San Francisco, San Francisco, CA
⁴Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O2.6 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies